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Abstract
Purpose To investigate whether the success rate of ICSI is
(1) related to the etiology of infertility or (2) adversely
affected by a family history of potential genetic disorders.
Methods All men with an ICSI indication in our hospital
between 1994 and 2005 were included in our cohort study.
Data on the ICSI process, etiology of infertility, and family
history were collected. ICSI success rates of infertility
subgroups and a subgroup with a positive family history
were compared to a group with unknown etiology and a
negative family history.
Results There was no significant difference in clinical
pregnancy or delivery rates between the subgroups.
Couples achieving a pregnancy underwent significantly
more ICSI cycles compared to couples not achieving a
pregnancy.
Conclusion Our results suggest that the success rate of ICSI
treatment is not related to the cause of infertility or a family
history positive for potential genetic disorders.
Keywords Etiology.Familyhistory.Intracytoplasmic
sperminjection.Maleinfertility.Successrate
Introduction
Since its introduction in 1991, intracytoplasmic sperm
injection (ICSI) has been a treatment option for couples
with male infertility. Worldwide it has an average pregnancy
success rate of 25–30% of pregnancies per treatment cycle.
Thisfigureisequal tothatofin vitro fertilization (IVF) [1–3].
In recent years the success rate of ICSI has not substantially
improved, despite new procedures such as preimplantation
genetic screening (PGS) [3–5]. Several studies have tried to
identify the underlying causes of the limited success rate of
ICSI, for example advanced maternal age or sperm origin
(testicular, epididymal or ejaculated). However, no good
explanation has been found yet [6–8].
On the basis of the etiology of in-/subfertility, different
subgroups of ICSI candidates can be distinguished:
obstructive azoospermia, including congenital uni- or
bilateral agenesis of the vas deferens (CUAVD or CBAVD)
caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene, and non-obstructive
in-/subfertility, which in a number of cases is caused by
either chromosomal abnormalities or Y-deletions [9, 10].
Another possible indicator of the ICSI success rate might
be found in the family history of couples with in-/
subfertility. A family history of congenital anomalies or
serious disorders might be, at least in part, genetically
determined and therefore reflect to some extent a decreased
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e-mail: m.maiburg@umcutrecht.nlviability of embryos/offspring in infertile couples. It is
possible that physiological or anatomical abnormalities
determine the fate of the fetus and modify the success rate
of ICSI.
We hypothesized that the success of ICSI treatment
could be related to the cause of infertility. We first aimed to
determine the prevalence of different etiological subgroups
in a large historical cohort of 1565 ICSI couples during the
first 11 years of the use of ICSI in our hospital. Secondly,
we investigated whether the success rate of ICSI was (1)
related to the etiology of infertility or (2) adversely affected
by a family history of potential genetic disorders.
Methods
Study population
ICSI treatment was introduced in the University Hospital in
Utrecht, the Netherlands, in 1994. From then to 2005 all
men with an indication for ICSI treatment were included in
our study (n=1565, of which 1487 had a genetic follow up,
see flowchart in Fig. 1). Indications for ICSI were severe
oligoasthenoteratozoospermia (OAT) [11] or total fertiliza-
tion failure in at least two previous in vitro fertilization
cycles. This means that males with normospermia could
also be included. There was a national moratorium in the
Netherlands on using surgically retrieved sperm for ICSI
during part of the study period (1996–2001), so that
ejaculated spermatozoa were used in the majority of cases,
explaining why a relatively low number of men with
obstructive azoospermia, such as CBAVD, were included in
this ICSI group. For those patients with obstructive
azoospermia, spermatozoa were surgically retrieved by
microsurgical epididymal sperm aspiration (MESA) or
percutaneous epididymal sperm aspiration (PESA).
Data collection
We performed a historical cohort study, obtaining data from
the medical records of ICSI candidates. As part of the ICSI
procedure, karyotyping was performed in all the males.
Soon after the introduction of ICSI, Y chromosome
deletion analysis was also introduced in the diagnostic
1487 with genetic follow up 
1565 ICSI candidates  78 refrained from 
genetic follow up 
+ ICSI treatment
177 ICSI 
positive family 
history 
213
control group 
randomly chosen 
213
negative family 
history 
547
161 ICSI 
obstructive 
azoospermia: 
 48 
Y-deletion 
testing:  1356 * 
results
karyotype: 
 1487 results 
aberrant 
karyotypes 
37
20 ICSI  14 ICSI  9 ICSI 
Y-deletions 
13
family forms: 
760 completed** 
*  somewhat lower compared to the total number of karyotyped cases because of the later 
   introduction of Y chromosome deletion analysis in the standard diagnostic procedure 
** 727 couples did not complete a family form and were excluded 
Fig. 1 Flowchart of study
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cases in which Y chromosome deletion analysis was
performed compared to the total number of karyotyped
cases). In case of CBAVD or obstructive azoospermia,
CFTR mutation analysis was performed. Couples were also
asked to complete a family history form on the occurrence
of 31 disorders in first-, second-, and third-degree relatives.
These disorders were classified into seven categories: (1)
spontaneous abortions, (2) stillborn children or children
who had died in the early postpartum period, (3) congenital
malformations, (4) mental retardation (not otherwise spec-
ified), (5) in-/subfertility, (6) multifactorial and/or late-onset
diseases (e.g., cardiovascular disease, cancer, epilepsy), and
(7) others (including consanguinity between partners). A
family history was considered aberrant (positive) if any
disorder in the above categories was reported. Couples with
a positive family history were informed about the possible
genetic risk by a clinical geneticist.
We recorded the number of treatment cycles, embryonic
transfers, and pregnancies for all couples. If a pregnancy
was achieved, we also documented the course (ongoing
pregnancies, abortions or stillbirths) and outcome (live born
children) of the pregnancies, as well as the number of
multiple pregnancies. Although congenital malformation
data were not systematically recorded, information on
serious congenital malformations was available in a few
cases. In July 2008 (3 years after the initial data collection),
the follow up data were collected.
Data analysis
ICSI couples were divided into the following subgroups:
(1) aberrant karyotyping, (2) Y-deletion, (3) obstructive
azoospermia, and (4) positive family history. From the
remaining couples without a positive family history (i.e.,
idiopathic infertility without any abnormalities recorded in
our subgroups), we chose a number of ICSI couples with
idiopathic infertility at random to serve as an internal
control group; this subgroup was the same size as the
positive family history group (Fig. 1).
The course of the ICSI treatment for the different
subgroups was recorded. We compared: (1) success in
terms of clinical pregnancy rate (number of pregnancies /
number of ICSI cycles), (2) success in terms of delivery
rate (number of pregnancies–number of abortions / number
of ICSI cycles), and (3) number of couples achieving at
least one clinical pregnancy or live born child (“success
couples”). Individual subgroups were compared to (1) the
internal control group and (2) the total of the remaining
subgroups.
The success rates were treated as numerical variables.
Statistical analysis was performed using the Mann–Whitney
or Chi-squared test. Data were examined for normality
using the Komorono–Smironof test, and a linear regression
model for success rate was fitted with multiple causes of
infertility.
Results
Prevalence of etiological factors of infertility
The prevalence of the causes of infertility and positive
family history in our study population is shown in
Table 1. The most prevalent cause of infertility was
obstructive azoospermia (3.2%) followed by an aberrant
male karyotype (2.5%) and Y-deletions (0.95%). The
azoospermia subgroup (n=48) included CBAVD (n=41),
CUAVD (n=1), and other forms of obstructive azoosper-
mia (n=6). A CFTR mutation was found in 27 cases
(56%): 14 patients were heterozygous for a CFTR
mutation (29%), one was homozygous (2%), and 12 were
compound heterozygous (25%). In the aberrant karyotyping
subgroup, Robertsonian translocations (27%) and sex
chromosomal aberrations (22%) were the most common
chromosomal abnormality. In the Y-deletion subgroup, a
deletion of either AZFc (11; 85%), AZFb+c (1; 8%), or AZFa
(1; 8%) was found.
There were 760 family forms available, of which 213
(28%) revealed a positive family history for one (or more)
of the disorders listed in Table 1. Three couples in the
aberrant karyotyping group, three couples in the obstructive
azoospermia group, but none in the Y-deletion group, also
had a positive family history.
Success rates
The course of ICSI treatment in the total cohort and the
different subgroups is shown in Table 2. In total, 1088 ICSI
cycles were performed in 381 candidates, yielding 361
pregnancies and 331 live born children. The overall
delivery rate (≥ 1 child born / ICSI cycle) was 27% (295/
1088). The success rates and ‘success couples’ for the
different subgroups are given in Table 3.
The clinical pregnancy rate and delivery rate for
couples with idiopathic male infertility (i.e., the internal
control group) was 33% and 25% respectively
(Table 3b). The clinical pregnancy rates of the other
categories were 41% (obstructive azoospermia, p=0.33),
37% (aberrant karyotype, p=0.51), 38% (Y-deletion, p=
0.55), and 33% (positive family history, p=0.99) respec-
tively. Compared to the control group there was no
significant difference in delivery rate for patients with
obstructive azoospermia (41%, p=0.50), patients with an
aberrant male karyotype (35%, p=0.13), patients with a
Y-deletion (34%, p=0.28), or patients with a positive
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significant difference in pregnancy- or delivery rate when
comparing the individual subgroups to the rest of the
cohort (data not shown).
Of the 161 couples with idiopathic infertility (i.e. the
internal control group), 102 (63%) achieved at least one
pregnancy (Table 3c), compared to 10 in the obstructive
azoospermia subgroup (71%, p=0.54), 14 in the aberrant
karyotype subgroup (70%, p=0.56), seven in the Y-deletion
subgroup (78%, p=0.38) and 125 of the positive family
history subgroup (71%, p=0.16).
Of the 161 couples of the control group, 89 (55%) had
at least one child after ICSI treatment, compared to ten
in the obstructive azoospermia subgroup (71%, p=0.24),
14 in the aberrant karyotype subgroup (70%, p=0.21),
seven in the Y-deletion subgroup (78%, p=0.19), and 112
of the positive family history subgroup (63%, p=0.13).
Discussion
A large cohort of 1565 ICSI couples was analyzed with
respect to the genetic causes of male infertility. We
analyzed the relationship between the causes of infertility
or a positive family history for potential genetic disorders
and ICSI success rates. We found no significant differences
for any of these subgroups with respect to the clinical
pregnancy and delivery rates. Many studies have looked at
factors influencing the outcome of ICSI [6–8], however, to
our knowledge, this is the first in which the possible
adverse effect of a positive family history was included.
Distribution of etiological subgroups
The rate we determined for male chromosome abnormali-
ties (2.5%) was somewhat lower than those reported in
Table 1 Prevalence of the causes of infertility in our study population (n=1487)
Causal Associated
Obstructive azoospermia
a Aberrant karyotype Y-deletion Positive family history
b
48/1487 37/1487 13/1365 213/760
(3.2%)
c (2.5%) (0.95%) (28.0%)
CFTR mutations 27 (56%) Robertsonian translocations 10 (27%) AZFa 1 (8%) (1) spontaneous abortions 40 (19%)
- heterozygous 14 (29%) sex chromosomal abnormalities 8 (22%) AZFb 0 (0%) (2) stillborn or postpartum (dead) 7 (3%)
- homozygous 1 (2%) reciprocal translocations 7 (19%) AZFc 11 (85%) (3) congenital malformations
d 37 (17%)
- compound
heterozygous
12 (25%) mozaisicm 6 (16%) AZFb+c 1 (8%) (4) mental retardation
e 24 (11%)
marker chromosomes 4 (11%) (5) in-/subfertility 6 (3%)
inversions 2 (5%) (6) multifactorial / late onset
f 48 (23%)
(7) other
g 54 (25%)
asubgroup includes CBAVD (n=41), CUAVD (n=1) and other forms of obstructive azoospermia (n=6)
bmore than one item can be positive in one familiy
crelatively low prevalence in this cohort due to the Dutch moratorium on using surgically retrieved sperm
dincluding club feet, cleft lip/palate, congenital heart malformations, hydrocephaly and neural tube defects
eincluding Down syndrome
fincluding cardiovascular disease, diabetes mellitus, cancer, epilepsy, asthma/bronchitis and allergies
gincluding cystic fibrosis, growth disorders, sertoli cell only syndrome and consanguinity
Table 2 Course of ICSI treatment
Control group Obstructive azoospermia Aberrant karyotype Y-deletion Positive family history Total
Couples starting ICSI
in our centre, n
161 14 20 9 177 381
ICSI cycles, n 448 29 54 29 528 1088
Embryonic transfers, n 396 24 48 25 462 955
Clinical pregnancies, n 146 12 20 11 172 361
Multiple pregnancies, n 17 3 1 0 15 36
Abortions, n 32 0 1 1 32 66
Live born children, n 131 15 20 10 155 331
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overall ICSI group [9, 12, 13]. This could be explained by
the fact that our study included mainly males with
ejaculated sperm due to a Dutch moratorium on using
surgically retrieved sperm for ICSI during a major part of
the study period. Therefore males with idiopathic azoo-
spermia (in whom the highest rates of chromosome
abnormalities can be found), were not included in this
study. Moreover, males with obstructive azoospermia were
documented as a separate group. In addition, one of the
indications for ICSI treatment was “total fertilization failure
in at least two previous IVF cycles”, thus including males
with normospermia as well. Compared to the published
rates of chromosome abnormalities in males with OAT, our
figures do not differ much from those of Bor et al. (2.7%)
[12], Tuerlings et al. (3.5%) [13], and Vincent et al. (0.5%
in mild and 4.3% in moderate OAT) [14].
The rate of Y-chromosome deletions in the DAZ region
(0.95%) in our study population was comparable to that
reported by Bor et al. (0.75% in an overall ICSI group) [12]
and somewhat lower compared to that by Cruger et al. (2%
in a severe OAT group) [15].
Our cohort of patients in whom surgically obtained
sperm were used consisted of patients with CBAVD (n=
41), CUAVD (n=1) and other forms of obstructive
azoospermia (n=6). The number of CFTR mutations found
in the latter group is usually smaller than that in the
CBAVD group [16]. The number of cases with double
allelic (13/48=27%) or monoallelic (14/48=29%) muta-
tions in the CFTR gene in our obstructive azoospermia
group seems to be lower than in previously published
reports, especially with respect to the double allelic
mutations. Mak et al. [16] reported two mutations in 40%
of CBAVD patients and 25% of obstructive azoospermia
patients (CBAVD, CUAVD and idiopathic obstruction), and
Claustres et al. [17] reported two mutations in 47% of
CBAVD patients). However, the numbers of mutations
reported in different publications show a wide variation. We
do not have a clear explanation for this discrepancy.
Overall, at least with respect to the small subset of genetic
Table 3 Outcomes of ICSI treatment
Control group Obstructive azoospermia Aberrant karyotype Y-deletion Positive family history
a) Couples and cycles
Couples starting ICSI in
our centre, n
161 14 20 9 177
Median number of cycles
per couple (range)
2.34 (1–10) 1.92 (1–5) 2.26 (1–8) 3.02 (1–6) 2.66 (1–10)
b) Success rates
Clinical pregnancies / ICSI
cycles (%)
33 41 37 38 33
Relative success (95% CI) – 1.24 (0.63–2.41) 1.12 (0.60–2.06) 1.15 (0.48–2.72) 1.00 (0.73–1.35)
Deliveries ≥ 1 child / ICSI
cycles (%)
25 41 35 34 27
Relative success (95% CI) – 1.64 (0.82–3.24) 1.4 (0.72–2.69) 1.36 (0.52–3.51) 1.08 (0.75–1.54)
c) (Un)successful couples
Couples achieving at least 1
pregnancy, n (%)*
102 (63) 10 (71) 14 (70) 7 (78) 125 (71)
Median number of cycles
per couple (range)
2.52 (1–10) 1.89 (1–5) 2.77 (1–8) 3.43 (1–6) 2.72 (1–10)
Couples not achieving
a pregnancy, n (%)
59 (37) 4 (29) 6 (30) 2 (22) 52 (29)
Median number of cycles
per couple (range)
2.11 (1–8) 2.00 (1–3) 1.80 (1–3) 2.50 (2–3) 2.19 (1–6)
Couples having at least on
child after ICSI
89 (55) 10 (71) 14 (70) 7 (78) 112 (63)
Median number of cycles
per couple (range)
2.52 (1–10) 1.89 (1–5) 2.77 (1–8) 3.33 (1–6) 2.56 (1–9)
Couples without children
after ICSI
72 (45) 4 (29) 6 (30) 2 (22) 65 (37)
Median number of cycles
per couple (range)
2.16 (1–8) 2.00 (1–3) 1.80 (1–3) 2.50 (2–3) 2.79 (1–10)
* = positive predictive value (PPV)
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similar to the other published ICSI cohorts.
With respect to the self-reporting of family history, we
realize that not everyone might have been equally accurate
in reporting disorders in family members. Couples who are
concerned about the risks for their progeny may report
more extensively than couples who are less concerned
about this risk, or whose only concern is to have children
after ICSI irrespective of any burden of familial disorders.
We cannot exclude that some couples in the negative family
history group were in fact non-reporters of a positive family
history and they should not therefore have been included in
the control group. Furthermore we are well aware that we
did not discriminate between the different categories of
reported disorders and the relationship of the affected
family member (more distant or close) on the one hand
and the ICSI outcome on the other hand. Therefore it cannot
be excluded that more serious disorders in close family
members have an adverse effect on ICSI outcome, whereas
milder disorders in more distant family members may not.
ICSI success rates
We compared the ICSI success rates of the different
etiological subgroups, including the positive family history
subgroup, to an internal control group (negative family
history). The rates for each of these subgroups were similar
or higher compared to the previously reported success rate
of ICSI treatment (25–30%) [1–3], ranging from 33–41% for
the clinical pregnancy rate and 25–41% for the delivery rate.
Interestingly, when comparing ICSI candidates with a
known etiology (i.e., either aberrant karyotype, Y-deletion,
or obstructive azoospermia) to the positive family history
group or control group, the last two groups turn out to have
the lowest success rates in this study. Although this
difference was not significant, we cannot exclude that
unknown genetic factors could, at least in part, explain the
infertility in these groups and influence the ICSI success
rates. On the other hand, the relatively high success rate in
the obstructive azoospermia group might be explained by
their essentially normal sperm production and that the
reason they need help is only due to a physical circum-
stance, such as obstruction.
The different subgroups were comparable with regard
to the mean number of cycles, number of multiple
pregnancies, and number of abortions. However, there
was a significant difference (p=0.013) between the mean
number of cycles in the overall group of couples achieving
at least one pregnancy compared to couples not achieving
a pregnancy (Table 3c). Accordingly, more ICSI cycles
lead to more couples having at least one child after
ICSI in the overall group, although the latter observa-
tion was not significant (p=0.192). For clinical practice,
this means that couples could be counselled towards
undergoing more cycles, expecting that success can still
be achieved regardless of the underlying aetiology. This
was to be expected for the control group. However, we
showed that also for the other subgroups, with the
exception of the obstructive azoospermia group that
already has a relatively high success rate, it is a low
number of cycles rather than the etiology which is the
cause of the low success rate.
One of the limitations in this study was that the overall
sizes of the subgroups were relatively small, although this
was a reasonably sized cohort of total ICSI candidates.
After intake and diagnostic investigations, a number of
candidates did not have ICSI treatment in our hospital (143/
524=27%). During the study period, waiting lists in
different hospitals varied considerably, leading couples to
‘shop around’. Some couples went abroad for ICSI
treatment because of the Dutch moratorium (see Methods).
Other couples opted for adoption, artificial insemination, or
IVF with donor sperm, or refrained from treatment because
of emotional burden. Previous studies have already shown
that 44% of males with a chromosomal aberration [18] and
21% of males with a Y-deletion [19] refrained from ICSI
treatment.
Despite the limitations of this study, our data from one
large cohort are interesting since we could compare the
success of ICSI treatment in different subgroups of in-/
subfertility, including one that has not been previously
studied, i.e., with a positive family history. We found no
significant relationship between the ICSI success rate and
the causes of male infertility. Probably evaluating the
various population-, cyto-, and molecular genetic features
may be of significance for counselling but they appear to be
of no value for prediction of the effectiveness of ICSI.
However, our subgroups were relatively small, and further
analysis in larger subgroups might yield different results. It
remains unclear whether the ICSI success rate is limited by
unknown factors or by factors inherent to the technique.
Conclusions
The success rate of ICSI treatment is neither related to the
cause of infertility nor adversely affected by a family
history positive for potential genetic disorders.
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